Charles River Laboratories (CRL) 8-K Current Report — February 25, 2026
Filed: February 25, 2026
Industrials
Services-Commercial Physical & Biological ResearchCharles River Laboratories (CRL) 8-K current report filed with SEC EDGAR on February 25, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 7.01: Regulation FD Disclosure
Charles River Laboratories 8-K Feb 25, 2026 Event Analysis
Item 7.01 · Regulation FD Disclosure
- • CDMO and Cell Solutions divested to GI Partners primarily for contingent performance-based payments — no meaningful upfront cash — combined 2025 revenue $143M
- • European Discovery Services sold to IQVIA for ~$145M cash plus up to $10M contingent; assets generated $144M in 2025 DSA segment revenue
Get deeper insights on Charles River Laboratories
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.